Newfound Research LLC decreased its position in Colgate-Palmolive (NYSE:CL) by 35.9% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 957 shares of the company’s stock after selling 536 shares during the period. Newfound Research LLC’s holdings in Colgate-Palmolive were worth $75,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently bought and sold shares of CL. Norges Bank purchased a new stake in Colgate-Palmolive in the 4th quarter worth approximately $742,997,000. American International Group Inc. lifted its position in Colgate-Palmolive by 390.4% in the 4th quarter. American International Group Inc. now owns 2,252,792 shares of the company’s stock worth $192,636,000 after buying an additional 1,793,428 shares in the last quarter. Robeco Institutional Asset Management B.V. lifted its position in Colgate-Palmolive by 82.1% in the 1st quarter. Robeco Institutional Asset Management B.V. now owns 2,579,172 shares of the company’s stock worth $203,316,000 after buying an additional 1,163,053 shares in the last quarter. Morgan Stanley lifted its position in Colgate-Palmolive by 22.9% in the 4th quarter. Morgan Stanley now owns 4,309,285 shares of the company’s stock worth $368,488,000 after buying an additional 801,541 shares in the last quarter. Finally, UBS Asset Management Americas Inc. raised its holdings in shares of Colgate-Palmolive by 12.5% during the 4th quarter. UBS Asset Management Americas Inc. now owns 4,545,448 shares of the company’s stock valued at $388,681,000 after purchasing an additional 505,307 shares in the last quarter. 76.47% of the stock is owned by hedge funds and other institutional investors.
Shares of CL traded up $0.60 on Tuesday, reaching $81.67. 132,808 shares of the company’s stock were exchanged, compared to its average volume of 4,888,717. The company has a current ratio of 0.97, a quick ratio of 0.62 and a debt-to-equity ratio of 6.50. The stock has a market capitalization of $69.22 billion, a P/E ratio of 25.96, a price-to-earnings-growth ratio of 3.83 and a beta of 0.59. The business has a 50 day moving average price of $78.89 and a two-hundred day moving average price of $80.70. Colgate-Palmolive has a 12 month low of $65.54 and a 12 month high of $86.41.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 14th. Investors of record on Wednesday, April 21st will be issued a dividend of $0.45 per share. The ex-dividend date of this dividend is Tuesday, April 20th. This represents a $1.80 dividend on an annualized basis and a yield of 2.20%. This is a boost from Colgate-Palmolive’s previous quarterly dividend of $0.44. Colgate-Palmolive’s payout ratio is currently 63.60%.
A number of research analysts have recently weighed in on the stock. Sanford C. Bernstein assumed coverage on shares of Colgate-Palmolive in a report on Tuesday, January 19th. They set an “underperform” rating and a $77.00 price target on the stock. Berenberg Bank upgraded shares of Colgate-Palmolive from a “sell” rating to a “hold” rating and set a $76.00 target price on the stock in a research note on Tuesday, January 26th. JPMorgan Chase & Co. lowered their target price on shares of Colgate-Palmolive from $87.00 to $85.00 and set a “neutral” rating on the stock in a research note on Thursday, April 22nd. Deutsche Bank Aktiengesellschaft raised their target price on shares of Colgate-Palmolive from $84.00 to $85.00 and gave the company a “hold” rating in a research note on Monday. Finally, Zacks Investment Research upgraded shares of Colgate-Palmolive from a “sell” rating to a “hold” rating and set a $85.00 target price on the stock in a research note on Monday. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and two have given a buy rating to the stock. Colgate-Palmolive has a consensus rating of “Hold” and a consensus price target of $82.92.
In other news, VP Philip G. Shotts sold 346 shares of the business’s stock in a transaction on Tuesday, February 16th. The shares were sold at an average price of $77.16, for a total value of $26,697.36. Following the sale, the vice president now owns 41,128 shares of the company’s stock, valued at $3,173,436.48. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider John W. Kooyman sold 463 shares of the business’s stock in a transaction on Tuesday, February 16th. The stock was sold at an average price of $77.16, for a total transaction of $35,725.08. Following the completion of the sale, the insider now directly owns 7,160 shares in the company, valued at approximately $552,465.60. The disclosure for this sale can be found here. Insiders sold 30,810 shares of company stock valued at $2,418,650 in the last quarter. Corporate insiders own 0.78% of the company’s stock.
Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment's products include toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other similar items.
Featured Article: Dividend Aristocrat Index
Want to see what other hedge funds are holding CL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Colgate-Palmolive (NYSE:CL).
Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.